Pacira BioSciences, Inc. — Director's Dealing 2014

May 10, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2014-05-09

Reporting Person: Brege Laura (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-05-09	Common Stock	M	7000	$10.81	Acquired	7000	Direct
2014-05-09	Common Stock	M	3000	$13.98	Acquired	10000	Direct
2014-05-09	Common Stock	S	7500	$73.57	Disposed	2500	Direct
2014-05-09	Common Stock	S	2500	$74.67	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-05-09	Stock Option (Right to Buy)	$10.81	M	7000	Disposed	2022-06-04	Common Stock (7000)	Direct
2014-05-09	Stock Option (Right to Buy)	$13.98	M	3000	Disposed	2021-06-02	Common Stock (3000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.93, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.00 to $74.83, inclusive.

F4: The stock options vest and become exercisable in twelve equal monthly installments, with the first installment on July 5, 2012.

F5: The stock options vest and become exercisable in 24 equal monthly installments beginning on July 2, 2011.